KIR2DL3 Protein - ACROBiosystems

Home
Products

Products by Category

Recombinant proteins and more
Multi-pass Transmembrane Proteins and Technology PlatformsNew FDA DMF Filed ProteinsHot SARS-CoV-2 Related ProductsHot Immune Checkpoint ProteinsHot Targets of CAR-T Cell TherapyNew CytokinesHot Biosimilar Drug TargetsHot Tumor MicroenvironmentHot Anti-idiotypic AntibodyHot Fc Receptor Proteins Llama IgG Fc Fusion ProteinNew Bio-Markers & CD Antigens ActiveMax -Best Cytokines Viral Proteins Enzymes Antibodies All Recombinant Proteins

Pre-labeled proteins
CAR rapid detection reagentsNew Biotinylated protein collectionHot FITC & PE labeled ProteinsNew Fluorescent fusion proteins
Kits
SARS-CoV-2 Related Kit ProductsNew Pre-Coupling Magnetic BeadsNew ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum Samples Inhibitor Screening Kits
Others
HPLC-verified Proteins Integrin - Integrin Proteins BCMA - B-Cell Maturation Antigen TIGIT - TIGIT Signaling Axis CD24 & Siglec-10 proteinsHot

Hot Products

Supports on COVID-19 R&D
Reagents for vaccine developmentNew Reagents for diagnostic developmentNew SARS-CoV-2 related productsNew SARS-CoV-2 related kitsNew SARS-CoV-2 mutant productsNew
Others
Multi-pass Transmembrane Proteins and Technology PlatformsNew Claudin18.2 ProteinsNew Bispecific antibody targetsHot Targets for ADCsHot IL-2 ReceptorsHot CD19 proteinsHot Anti-FMC63 mAbHot CD3 proteinsHot B7 family proteinsHot TNFSF proteinsHot VEGF proteinsHot CD39/CD73 proteinsNew Siglec-15 proteinsHot CD20 proteinsExclusive PD1 proteinsHot
Services

Innovation Lab
SPR /BLI analytical serviceNew Anti-Idiotypic AntibodyNew Enzyme-Linked Immunosorbent Assay (ELISA) Service New
Licensing Opportunities
Anti-TIM-3 monoclonal antibody New Anti-LAG-3 monoclonal antibody New Target 4-1BB monoclonal antibody New
Supports

How to Order Shipping & Payments Global Distributors Testimonials Download Brochures Download COA
Applications

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression
Company

About Us Join Us Contact Us
Activities

News Exhibitions Promotion
COVID-19 R&D ^New

KIR2DL3

Brief Information

Name:Killer cell immunoglobulin-like receptor 2DL3
Target Synonym:P58.2 MHC Class-I Specific NK Receptor,MHC Class I NK Cell Receptor,CD158b2 Antigen,KIR-K7b,KIR-K7c,KIR2DS5,CD158b,KIR2DL,NKAT2A,NKAT2B,GL183,NKAT,P58,Receptors, KIR2DL3,Cl-6,Killer Cell Immunoglobulin-Like Receptor Two Domains Long Cytoplasmic Tail 3,Nat

Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical


KI3-H5257	Human	Human KIR2DL3 / CD158b2 Protein, Fc Tag

Cat. No.

Species

Product Description

Structure

Purity

Feature

KI3-H5257

Human

Human KIR2DL3 / CD158b2 Protein, Fc Tag

Synonym Name

KIR2DL3,CD158B2,KIRCL23,NKAT2,KIR-023GB,NKAT2a,NKAT2b,NKAT-2,CD158 B2,GL183,KIR-023GB,KIR-K7b,KIR-K7c,KIRCL23,NKAT,p58

Background

Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) is also known as CD158 antigen-like family member B2, KIR-023GB, Killer inhibitory receptor cl 2-3, MHC class I NK cell receptor, NKAT2a, NKAT2b, Natural killer-associated transcript 2, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158b2 and KIR2DL3, which is a single-pass type I membrane protein and belongs to the immunoglobulin superfamily.KIR2DL3 is a receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). KIR2DL3 can inhibit the activity of NK cells thus preventing cell lysis.

Clinical and Translational Updates

Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	Phase 2 Clinical	Novo Nordisk A/S	Solid tumours; Head and Neck Neoplasms; Neoplasms; Hodgkin Disease; Smoldering Multiple Myeloma; Myelodysplastic Syndromes; Multiple Myeloma; Urinary Bladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell	Details